Classes
DEA Class; Rx
Common Brand Names; Pamelor, Aventyl
- Antidepressants, TCAs
Description
Tricyclic antidepressant (TCA) of the dibenzocycloheptene type; active metabolite of amitriptyline
FDA-approved for major depression in adults; common off-label uses for neuropathic pain and anxiety disorders in adults.
Boxed warning for use in pediatric patients and young adults due to risk for suicidality
Indications
Indicated for the treatment of major depression.
Contraindications
Hypersensitivity
Any drugs or conditions that prolong QT interval
Acute recovery post-MI
Adverse Effects
- Fatigue
- Lethargy
- Sedation
- Weakness
- Dry mouth
- Constipation
- Blurred vision
- Agitation
- Anxiety
- Headache
- Insomnia
- Nausea
- Vomiting
- Sweating
- Orthostatic hypotension, ECG changes, tachycardia
- Confusion, extrapyramidal symptoms, dizziness, paresthesia, tinnitus
- Rash
- Increased LFTs
- Sexual dysfunction
- Seizure
- Agranulocytosis
- Eosinophilia
- Leukopenia
- Thrombocytopenia
- SIADH
- Brugada syndrome
Warnings
Use cautioni in patients with BPH, urinary/GI retention, hyperthyroidism, seizure disorder, brain tumor, respiratory impairment, bipolar/mania (may worsen psychosis)
Clinical worsening and suicidal ideation may occur despite medication in adolescents and young adults (18-24 years)
Potentially life-threatening serotonin syndrome reported when coadministered with drugs that impair serotonin metabolism (in particular, MAOIs, including nonpsychiatric MAOIs, such as linezolid and IV methylene blue)
Risk of anticholinergic side effects
May cause bone marrow suppression (rare)
May cause orthostatic hypotension
May cause sedation, which may impair physical or mental abilities; use caution when performing tasks that require mental alertness (eg, operating heavy machinery)
Risk of mydriasis; may trigger angle closure attack in patients with angle closure glaucoma with anatomically narrow angles without a patent iridectomy
May cause sedation and impair physical or mental abilities
Withdraw gradually
Bone fractures have been associated with antidepressant treatment; consider possibility of bone fractures in patients if antidepressant treated patient presents with unexplained bone pain, swelling, bruising or point tenderness
Use with caution in patients who would not tolerate frequent hypotensive episodes, including patients with cardiovascular disease, hypovolemia or with concurrent medication that predisposes for hypotension/bradycardia
Use caution in patients with cardiovascular disease, diabetes mellitus (may alter glucose regulation), hepatic/renal impairment, and the elderly
Abrupt discontinuation or interruption of antidepressant therapy has been associated with a discontinuation syndrome, which may include vomiting, diarrhea, headaches, dizziness, chills, tremors, paresthesias, somnolence, fatigue, and sleep disturbances
May increase the risk of adverse effects associated with electroconvulsive therapy; discontinue therapy prior to electroconvulsive therapy if possible
Due to risk of drug interaction with anesthesia and of cardiac arrhythmia, discontinuation of therapy prior to elective surgery recommended
Association between treatment and the unmasking of Brugada syndrome with some resulting in death reported; therapy should generally be avoided in patients with Brugada syndrome or those suspected of having Brugada syndrome
Pregnancy and Lactation
Pregnancy category: D
Lactation: Excreted in breast milk; do not nurse (AAP states effect on nursing infants is unknown but may be of concern)
Maximum Dosage
150 mg/day PO.
50 mg/day PO.
50 mg/day PO.
Safety and efficacy have not been established.
How supplied
Nortriptyline hydrochloride
capsule
10mg
25mg
50mg
75mg
oral solution
10mg/5mL